Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring

American Journal of Health-System Pharmacy

Volumn 72, Issue 17, 2015, Pages S90-S97

  Frugé, Kristian S ^a   Lee, Young R ^b  

^a OUR LADY OF THE LAKE REGIONAL MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; ANTICOAGULANT AGENT;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ACUTE CORONARY SYNDROME; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLOOD CLOTTING TIME; BLOOD SAMPLING; BODY MASS; CLINICAL EVALUATION; ELECTRONIC MEDICAL RECORD; FEMALE; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM; BLOOD CLOTTING TEST; CLINICAL PROTOCOL; COMMUNITY HOSPITAL; HOSPITAL BED CAPACITY; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION TESTS; CLINICAL PROTOCOLS; FACTOR XA; FEMALE; HEPARIN; HOSPITAL BED CAPACITY, 500 AND OVER; HOSPITALS, COMMUNITY; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDIES;

EID: 84973412486     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/SP150016     Document Type: Article

References (16)

1. Rosborough TK. In unfractionated heparin dosing, the combination of patient age and estimated plasma volume predicts initial antifactor Xa activity better than patient weight alone. Pharmacotherapy. 1998; 18:1217-1223.
2. Smith ML, Wheeler KE. Weight-based heparin protocol using antifactor Xa monitoring. Am J Health-Syst Pharm. 2010; 67:371-373.
3. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994; 154:49-56.
4. Rosborough TK. Comparison of antifactor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin treated patients. Am J Clin Pathol. 1997; 108:662-668.
5. Bates SM, Weitz JI, Johnston M, Hirsch J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med. 2001; 161:385-391.
6. Rosborough TK, Shepherd MF. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy. 2004; 24:713-719.
7. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 1998; 114(suppl):561S-578S.
8. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998; 114(suppl):489S-510S.
9. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998; 122:782-798.
10. Rosenberg AF, Zumberg M, Taylor L, LeClaire A, Harris N. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy. Journal of Pharmacy Practice. 2010; 23:210-216.
11. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(suppl 2):e24S-e43S.
12. Guervil DJ, Rosenburg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother. 2011; 45:861-868.
13. Raschke RA, Reilly BM, Guidry JR, et al. The weight based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med. 1993; 119:874-881.
14. Rosborough TK. Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time. Pharmacotherapy. 1999; 19(6):760-766.
15. Bussey HI. Problems with monitoring heparin anticoagulation. Pharmacotherapy. 1999; 19(1):2-5.
16. Miller AE, Montague D, Rodgers JE, Sanghvi S, Whinna HC, Krumnacher H. Substitution of a heparin correlation value for activated partial thromboplastin time in heparin nomograms. Am J Health-Syst Pharm. 2011; 68:893-898.